Our early-stage drug discovery service delivers a comprehensive, data-rich platform covering target identification/validation, hit-to-lead optimization, lead-to-candidate progression/preclinical candidate selection. A distinctive feature is the integration of Proof-of-Concept/Efficacy studies and full ADMET profiling- both in vitro and in vivo- from the earliest phases to de-risk programs and ensure translational confidence. Key activities include high-throughput screening, hit/lead identification, iterative SAR/SPR-guided medicinal chemistry optimization, early in vitro/in vivo efficacy studies in disease-relevant models, and comprehensive ADMET characterization (permeability, metabolic stability, CYP, hERG, in vivo PK, tolerability, and preliminary toxicology). Supported by a multidisciplinary team (medicinal chemistry, pharmacology, DMPK/ADMET, in vivo pharmacology, bioinformatics), projects are fully customized to client target product profiles and timelines, typically lasting from a few months to over a year. Expected outcomes include the delivery of optimized preclinical candidates, supported by robust data packages that facilitate a smooth transition into the next phases of drug development. Each project is tailored to meet specific client objectives, ensuring high-quality results and a clear path forward for further development. This integrated, translation-focused approach significantly reduces late-stage attrition and enables seamless progression into IND-enabling studies and clinical development for pharmaceutical companies, biotech firms, and research institutions.